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Abstract 
Adeno-associated virus (AAV) vectors are important delivery platforms for therapeutic 
genome editing but are severely constrained by cargo limits, especially for large 
effectors like Cas9s. Simultaneous delivery of multiple vectors can limit dose and 
efficacy and increase safety risks. The use of compact effectors has enabled single-AAV 
delivery of Cas9s with 1-3 guides for edits that use end-joining repair pathways, but 
many precise edits that correct disease-causing mutations ​in vivo ​ require 
homology-directed repair (HDR) templates. Here, we describe single-vector, ~4.8-kb AAV 
platforms that express Nme2Cas9 and either two sgRNAs to produce segmental 
deletions, or a single sgRNA with an HDR template. We also examine the utility of 
Nme2Cas9 target sites in the vector for self-inactivation. We demonstrate that these 
platforms can effectively treat two disease models [type I hereditary tyrosinemia (HT-I) 
and mucopolysaccharidosis type I (MPS-I)] in mice. These results will enable 
single-vector AAVs to achieve diverse therapeutic genome editing outcomes.  
 
Introduction 
Bacterial and archaeal adaptive immune systems known as clustered, regularly interspaced, 
short, palindromic repeats (CRISPR), along with their CRISPR-associated (Cas) proteins, have 
been at the center of the RNA-guided genome engineering revolution ​1,2​, including genome 
editing ​3–11​. The most widely adopted CRISPR-Cas genome editing platforms​12,13​ are the Cas9 
endonucleases that create double-strand breaks (DSBs) in target DNA sequences 
complementary to a designed single-guide RNA (sgRNA). In addition to the sgRNA, Cas9 
requires the presence of a protospacer adjacent motif (PAM), which is a specific sequence 
proximal to the sgRNA-complementary target sequence ​1,2,14,15​. Once cleaved, the cell relies on 
the DNA repair machinery to resolve these DSBs through non-homologous end joining (NHEJ), 
microhomology-mediated end joining (MMEJ), or homology-directed repair (HDR), the latter of 
which can enable a wide range of precisely determined repair outcomes​16​. More recently, base 
editing ​17​ and prime editing ​18​ have emerged as promising technologies for achieving 
DSB-independent precision genome editing ​13​. 
The most widely used Cas9 homologue has been ​Streptococcus pyogenes​ Cas9 [SpyCas9, 
1,368 amino acids (aa)]​1,19​, which exhibits robust editing efficiencies, as well as a broad 
targeting range due to its short 5’-NGG-3’ PAM​1​. Additional targeting events have been enabled 
by SpyCas9 engineering to alter or reduce PAM requirements, and by identifying additional 
Cas9 homologs that are also active in eukaryotic cells but require distinct PAMs​13​. Some Cas9 
homologs, including Sth1Cas9 (1,120 aa)​3​, Nme1Cas9 (1,082 aa)​20,21​, SauCas9 (1,053 aa)​22​, 
CjeCas9 (984 aa)​23​, Nme2Cas9 (1,082 aa)​24​, and SauriCas9 (1,061 aa)​25​ are substantially 
smaller. The reduced sizes are important for some modes of ​in vivo​ delivery, especially viral 
vectors such as AAV, which has great potential as a delivery modality but is severely 
constrained in cargo size (<5 kb in most cases)​26​. Delivery of most of these compact Cas9s 
within single-vector AAVs, in which both the Cas9 and its sgRNA are packaged into the same 
virion, has been validated ​ in vivo​22–24,27,28​. AAV vectors encoding SauCas9 along with two 
sgRNAs​29,30​, as well as CjeCas9 with three sgRNAs​31​, have also been reported, enabling the 
introduction of multiplexed edits or segmental deletions. A few of the smaller Cas9s are also 
less prone to off-target cellular editing than wild-type SpyCas9 ​23,24,27,32,33​, even with guides that 
support efficient on-target editing, likely because of reduced enzymatic efficiencies that 
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disproportionately dampen activity at near-cognate sites​34​. 
Despite the positive attributes conferred by Sth1Cas9, Nme1Cas9, SauCas9, and CjeCas9, 
they suffer from a more restricted targeting range than what is imparted by SpyCas9, due to 
their more complex PAMs that are less abundant throughout the genome. Engineering of the 
PAM-interacting domain of SauCas9 reduced its wildtype PAM requirements (5’-NNGRRT-3’)​22 
to 5’-NNNRRT​35​, helping to expand its targeting flexibility. More recently, Nme2Cas9 
(5’-NNNNCC-3’ PAM)​24​ and SauriCas9 (5’-NNGG-3’ PAM)​25​ were discovered as natural 
compact Cas9s with dinucleotide PAMs. To our knowledge, the ​in vivo​ utility of SauriCas9 in 
all-in-one AAV vectors is yet to be documented.  
To date, ​in vivo​ genome editing applications by recombinant AAV (rAAV)-encoded Cas9 have 
mostly been limited to gene knockouts or insertions by cleavage events that are repaired by 
NHEJ pathways. Precise editing that introduces specific sequence changes that are not 
compatible with mismatch-mediated end joining (MMEJ) repair​36,37​ are very difficult to attain via 
HDR​ in vivo​ due in part to the requirement for co-delivery of a repair template, in addition to the 
low or absent activity of the HDR pathway in non-cycling cells, or during the G1 phase of the cell 
cycle ​16​. Co-delivery of multiple AAV vectors for HDR-based precise editing ​in vivo​, e.g. with the 
Cas9 effector on one vector, the donor on another, and the sgRNA(s) encoded by either or both 
vectors, has shown some promise in animal models​38–40​. Other strategies for precise editing ​in 
vivo​, such as base editing and prime editing, involve Cas9-fused effectors that are sufficiently 
large as to again require two vectors​41–45​. However, the combined AAV dosages required for 
multi-vector strategies raise significant concerns about safety during clinical translation ​46,47​, 
especially in light of recent events in human trials of a high-dose AAV gene therapy​48​. A recent 
report described a single-AAV system in which SauCas9, two sgRNAs, and an HDR donor were 
designed into a single >5 kb vector construct​49​. However, this study used an AAV8 capsid that 
lacks the VP2 subunit, yielding low vector titers with the increased cargo size. Precise genome 
editing strategies compatible with single-vector AAVs using well-established capsids that can be 
produced at pre-clinical and clinical scales are therefore still needed. 
By building upon the compact size, high cellular editing accuracy, and targeting flexibility of 
Nme2Cas9 ​24,50​, we have systematically engineered novel all-in-one AAV:Nme2Cas9 vector 
systems with increased utility beyond that afforded by our initial version ​24​, which encoded the 
effector and just one sgRNA. First, we showed that minimizing the Nme2Cas9 cassette, its 
regulatory elements, and the sgRNA provided additional coding capacity that could be used to 
incorporate a second sgRNA. Specific arrangements and orientations of the dual-sgRNA 
system were validated for their capacity to be packaged into a single AAV vector, and for their ​in 
vivo ​efficiencies in introducing two DSBs. This strategy successfully induced exon excision or 
inversion ​in vivo​ to rescue the disease phenotype of type I hereditary tyrosinemia (HT-I) mice. 
We then demonstrated that one of the two sgRNA cassettes could be replaced by an HDR 
donor, while remaining below the 5 kb cargo size required for efficient packaging into standard 
serotypes. We further endowed this system with Nme2Cas9 target sites flanking the HDR donor 
to allow self-inactivation of the vector as a function of editing effector accumulation. To enable 
vector packaging of a self-targeting nuclease system, we employed an anti-CRISPR (Acr) 
protein ​51,52​ to prevent self-cleavage during vector cloning and packaging. The ​in vivo ​efficiency 
of this all-in-one HDR-based Nme2Cas9 editing system was validated in two mouse models of 
inherited disease [the metabolic disorder HT-I and the lysosomal storage disease 
mucopolysaccharidosis type I (MPS-I)]. In both cases, precise editing efficiencies reached levels 
sufficient for therapeutic benefit. The establishment of a self-inactivating single-rAAV system 
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capable of precise, versatile, HDR-based genome sequence changes ​in vivo​, combined with the 
accuracy and wide targeting range of Nme2Cas9, provide important new capabilities for the 
development of more potent therapeutic genome editing platforms. 
  
Results 
Development of a gene-editing rAAV construct with a minimized Nme2Cas9 payload. ​We 
previously engineered ~4.7-kb rAAV gene editing vectors that deliver Nme1Cas9 or Nme2Cas9 
and a 145 nucleotide (nt) sgRNA​24,27​. Both Cas9 transgenes were fused with four nuclear 
localization signals (NLSs) and a triple-HA epitope tag. To engineer a single Nme2Cas9 vector 
with additional capabilities, we created a shortened Nme2Cas9 + sgRNA backbone. Directed by 
Nme2Cas9 structural information ​53​ as well as empirical testing of guide requirements, we 
truncated the repeat:anti-repeat duplex to create two shortened 121-nt and 100-nt sgRNAs 
(Nme.sgRNA-121 and Nme.sgRNA-100, respectively) (​Supplementary​ Fig. 1). The truncated 
guides were cloned into the previously published Nme2Cas9 AAV backbone ​24​. Comparison of 
editing efficacy at the ​CYBB​, ​LOC100505797​,​ ​and ​Fah ​genomic loci by plasmid transfection into 
HEK293T (human) and Neuro2a (mouse) cells showed that Nme.sgRNA-100 partially 
compromises Nme2Cas9 activity, while Nme.sgRNA-121 performance is more consistent and 
comparable to that of full-length Nme.sgRNA (​Supplementary​ Fig. 1). Although 
Nme.sgRNA-100 performance was less consistent by plasmid transfection when driven by a U6 
promoter, ​ex vivo ​editing by Nme2Cas9 following ribonucleoprotein (RNP) delivery using a 
chemically synthesized Nme.sgRNA-100 was robust. We systematically compared editing 
efficiencies using full-length and 100-nt sgRNAs that were made by T7 ​in vitro​ transcription 
(IVT), with and without calf intestinal alkaline phosphatase (CIP) treatment​54​, and commercial 
synthetic guides carrying three 2’-​O​-methyl phosphorothioate modifications at each end to 
protect against exonucleases​55​. Our editing data in HEK293T cells and the difficult-to-transfect T 
lymphoblast cell line MOLT-3 showed that the truncated Nme.sgRNA-100 conferred a higher 
editing efficiency compared to the other sgRNA formats when delivered as electroporated RNPs 
(​Supplementary​ Fig. 1). Shortening to 100 nt places Nme2Cas9 sgRNAs within the size range 
needed for facile chemical synthesis for RNP delivery.  
Because the 121-nt sgRNA version was more consistent as an intracellular transcript, we used it 
to create a shortened AAV:Nme2Cas9 vector. Using Nme.sgRNA-121 (henceforth referred to as 
sgRNA), a short polyadenylation signal ​56​, and an Nme2Cas9 open reading frame (ORF) with 
two NLSs and no epitope tags, we generated a minimized AAV:Nme2Cas9:sgRNA vector with a 
total genome size of ~4.4 kb (​Supplementary​ Fig. 1; Supplementary Note). We used plasmid 
transfection into HEK293T and Neuro2a cells to compare the editing activity of the shortened 
construct to that of the previously published 4.7-kb AAV:Nme2Cas9:sgRNA backbone. 
Sequencing analysis indicated that the shortened AAV backbone is functional in cells with 
comparable editing efficiencies at three of the four sites tested (​Supplementary​ Fig. 1). Overall, 
our results confirmed that the shortened AAV:Nme2Cas9 construct is efficient at genome 
editing, affording additional cargo capacity to expand functionality. 
Design of dual-sgRNA AAV:Nme2Cas9 vectors. ​Previous reports have shown that when two 
simultaneous DSBs occur, the NHEJ pathway can re-ligate the free DNA ends to produce a 
segmental deletion ​30,57–60​. The delivery of two guides within the same AAV vector can support 
this form of editing, facilitate the simultaneous knockout of two distinct targets, or enable the use 
of paired nickases via single-rAAV delivery​29​. However, as with strong secondary structural 
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elements in general ​61,62​, the inclusion of two sgRNA cassettes in the same backbone can 
present significant obstacles to such designs by inducing the formation of truncated vector 
genomes​63​. To address such events, we engineered AAV:Nme2Cas9 constructs carrying two 
sgRNA-121 cassettes in various positions and orientations (Fig. 1a). Each of these four 
backbones was packaged into AAV8 capsid and the viral DNA was isolated ​64​. Size comparisons 
using alkaline agarose gel electrophoresis analysis revealed that depending on the sgRNA-121 
cassette orientation and position, the genomes of certain dual-sgRNA AAV vectors indeed 
produced multiple truncated forms. Two designs (henceforth referred to as Dual-sgRNA:Designs 
1 and 4; Supplementary Note) appear to contain predominantly full-length, non-truncated 
~4.8-Kb genomes (Fig. 1b). 
To test the efficacy of these constructs for the induction of segmental deletion, we tested Design 
1 and Design 4 for their capacity to excise a 606-bp fragment spanning exons 3 and 4 of the 
Hpd​ gene (Fig. 1c). We did this first in cultured cells and then in an HT-I mouse model in which 
the ​Fah​ gene, which encodes the liver enzyme fumarylacetoacetate hydrolase (FAH), is 
disrupted by the insertion of a neomycin cassette in exon 5 (​Fah​neo/neo​)​65​. A hallmark of this 
disease in mice is the gradual loss of body weight when the mice are not maintained on water 
supplemented with the drug 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), 
which blocks the tyrosine catabolism pathway upstream of FAH, preventing the buildup of the 
hepatotoxic metabolites that result from loss of FAH​66​. Knocking out HPD​ ​can rescue the lethal 
phenotypes of HT-I mice by blocking the tyrosine catabolic pathway upstream of FAH​27,67​. In 
addition to the expected segmental DNA deletion, we also anticipated detecting inversions and 
small indels at one or both of the two target sites​30,60,68​. Initially we transfected 
Dual-sgRNA:Design 1 and Dual-sgRNA:Design 4 plasmids into mouse Neuro2a cells and used 
single molecule, real-time (SMRT) sequencing to assess editing efficiency, using primers that 
included unique molecular identifiers (UMIs) to enable correction for amplification bias with 
products of different lengths. Our analysis showed that both of these plasmids efficiently yielded 
the expected segmental deletion only when spacers gRNA-I and gRNA-II are co-expressed. Our 
data also revealed that localized, small insertions/deletions (indels) are generated at both target 
sites when segmental deletion does not occur (Fig. 1d,e and Supplementary Fig. 2). In addition 
to confirming that co-expression of Nme2Cas9 and two sgRNAs can efficiently induce 
segmental deletions in cultured cells​24​, these results also affirm that dual-sgRNA AAV 
backbones should be carefully evaluated to avoid formation of truncated genomes that may 
compromise vector performance ​in vivo​63​. 
Validation of dual-sgRNA AAV:Nme2Cas9 gene editing ​in vivo. ​ ​To test the ability of 
dual-sgRNA AAV:Nme2Cas9 vectors to disrupt ​Hpd ​in HT-I mice, we used the two validated 
AAV8:Nme2Cas9 Dual-sgRNA:Design 1 and 4 vectors (Fig. 1b) to induce segmental deletion of 
exons 3 and 4 ​in vivo​ in ​Fah​neo/neo​ mice. Adults were injected with 4 x 10 ​11​ gc of each vector via 
tail vein. To assess baseline editing efficiency without selective clonal expansion of edited 
hepatocytes, we evaluated editing in one mouse from each group prior to NTBC withdrawal, as 
well as in C57BL/6 mice (Fig. 2a). After NTBC withdrawal, ​Fah​neo/neo​ mice were effectively 
rescued of the lethal phenotypes of HT-I as indicated by body weight stability for 3 weeks (Fig. 
2b). In contrast, PBS-injected ​Fah​neo/neo​ mice lost over 10% of their body weights within 4-13 
days of NTBC withdrawal and were euthanized (Fig. 2b).  
After completion of editing regimens, we harvested liver DNA and performed UMI-augmented 
SMRT sequencing of target-spanning amplicons for all mice in the study to assess the 
efficiencies of segmental deletion and other outcomes. These analyses revealed that segmental 
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deletions were successfully induced by Nme2Cas9 ​in viv​o with both dual-sgRNA vector designs 
(Fig. 2c), with the expected 3.0 kb read lengths resulting from deletion of the 606-bp fragment 
from the 3.6-kb amplicon (​Supplementary​ Fig. 2). In C57BL/6 mice, which are not expected to 
exhibit selective proliferation of edited cells, treatment with dual-sgRNA:Designs 1 or 4 
produced 50.5 ± 8.7% and 33.6 ± 6% segmental deletions between the two target sites, 
respectively (Fig. 2c). With the ​Fah​neo/neo​ cohorts treated with each vector design, the mice 
analyzed before NTBC withdrawal exhibited 33.3% (Design 1) and 15.8% (Design 4) segmental 
deletion efficiencies. Three weeks following NTBC withdrawal and selective hepatocyte 
expansion, vector designs 1 and 4 yielded 35.7 ± 3.3% and 33.2 ± 4% segmental deletions, 
respectively. Surprisingly, inversions were detected at lower frequencies than previously 
demonstrated (Fig. 2c)​30,60​. In addition to segmental deletions, significant frequencies of small 
indels were observed at the two target sites (Fig. 2d). Vector fragment integration at the DSB 
sites were detected at a frequency of 2.8 ± 0.7% (Design 1) and 2.4 ± 0.8% (Design 4) in 
C57BL/6 mice, at 2.3% (Design 1) and 1.5% (Design 4) before NTBC withdrawal, and 3.5 ± 
0.5% (Design 1) and 2.7 ± 0.5% (Design 4) post-NTBC withdrawal (​Supplementary​ Fig. 2). 
We extensively characterized genome-wide mRNA levels using mRNA extracted from mouse 
livers by mRNA sequencing. Our data revealed that efficient segmental deletion in recovered 
Fah​neo/neo​ cohorts treated with each dual-sgRNA vector design yielded ​Hpd​ mRNA levels that 
were lower than those observed in healthy, PBS-treated wild-type mice (Figs. 2e and 2f). ​Hpd 
mRNA levels were also strongly reduced (relative to PBS-treated C57BL/6 mice) in 
PBS-injected ​Fah​neo/neo​ animals, presumably as a secondary consequence of extensive liver 
damage. ​Hpd​ mRNA levels were significantly decreased in C57BL/6 mice treated with either of 
the dual-sgRNA vectors (Fig. 2e), reflecting the expected results of Nme2Cas9 editing. Globally, 
4,792 and 5,027 genes were significantly differentially expressed in ​Fah​neo/neo​ mice after 
treatment with Dual-sgRNA:Design 1 and 4 vectors, respectively (FDR <= 5%, relative to PBS 
treatment). Differentially expressed genes were enriched within similar gene ontology categories 
across the two dual-sgRNA treatments, with an enrichment of genes in metabolic processes, 
regulation of endopeptidase activity, and response to external stimulus (Supplementary Table). 
In both cohorts of mice, there was a decrease in the inclusion of exons 3 and 4 in mature ​Hpd 
mRNA transcripts (Fig. 2g), with both exons 3 and 4 being skipped in 4.2-5.5% of transcripts 
(compared to 0.08% of transcripts in PBS treated mice). More strikingly, due to the proximity of 
gRNA-II to the splice donor site (Fig. 1c), exon 4 is excluded in 86.7-87.5% of ​Hpd​ mRNAs in 
dual-sgRNA treated mice (compared to 0.33% of transcripts in PBS treated mice) 
(Supplementary Fig. 2). Consistent with the observed prevalence of segmental deletions, 
inversions, skipped exons and other perturbations (Fig. 2c,d), our protein analyses showed 
efficient knockdown of HPD in the livers of the edited ​Fah​neo/neo​ ​and C57BL/6 mice by Western 
blot (Fig. 2f) and immunohistochemistry (Fig. 2g; ​Supplementary​ Fig. 2). These data 
demonstrate that Dual-sgRNA:Designs 1 and 4 are effective vectors for inducing segmental 
DNA deletions ​in vivo​. 
Design of self-eliminating rAAV:HDR vectors. ​The majority of rAAV-based applications to 
repair pathogenic mutations ​in vivo​ rely on a two-vector system for the delivery of Cas9 in one 
rAAV and the HDR donor (along with the guide) in another​38,69,70​. Although this strategy allows 
control over dosing at different donor:effector ratios, it also requires higher overall vector doses, 
which might be toxic to the patient. Furthermore, the lack of simultaneous transduction with both 
vectors in a percentage of cells will limit editing efficiencies. Previously, HDR-based precision 
editing platforms involving simultaneous delivery of Cas9, sgRNA, and donor DNA in a single 
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vehicle generally used adenoviral vector​71​ or RNP​72,73​ delivery, neither of which can reach all cell 
types of clinical interest. To extend single-vehicle HDR-based gene editing to AAV vectors that 
are within the standard limits of efficient packaging (​~​4.9 kb) with well-characterized capsids, we 
engineered rAAV backbones containing Nme2Cas9, sgRNA and a <500-nt donor DNA for ​in 
vivo​ testing of HDR editing. 
To examine the best placement of the donor DNA within the rAAV backbone, we first created 
two designs in which the donor was placed near the 3’ ITR (design A) or in the middle of the 
backbone (design B) (Fig. 3a). We also created designs C and D, which respectively differ from 
A and B only in the presence of Nme2Cas9 sgRNA target sites flanking the donor (Fig. 3a). The 
presence of Cas9 target sites that flank an HDR donor has previously been shown to increase 
HDR efficiencies in cell culture after plasmid transfection ​74​. These rAAV:HDR:cleaved designs 
also have the potential to enable self-elimination of the AAV:Nme2Cas9 vector, limiting or 
preventing long-term Cas9 expression ​ in vivo​75–77​ that could exacerbate off-target mutagenesis, 
genotoxicity, and immunogenicity. 
The major hurdle in creating the rAAV:HDR:cleaved design C and D backbones was the 
degradation of the plasmids after transformation in ​E. coli​ competent cells due to leaky 
expression of Nme2Cas9 and sgRNA in bacteria. To resolve this issue, we used λred phage 
recombineering technology​78​ to integrate the ​H. parainfluenzae​ anti-CRISPR ​acrIIc4​Hpa​ gene ​
79​, 
under the control of its native promoter, into DH5α competent ​E. coli​ cells to inhibit Nme2Cas9 
and prevent plasmid degradation. These plasmids were tested in a Traffic Light Reporter (TLR) 
system​80​, TLR-Multi-Cas-Variant 1 (MCV1), that has a disrupted GFP coding sequence followed 
by an out-of-frame mCherry cassette ​81​. The reporter cassette was inserted as a single copy via 
lentiviral transduction in HEK293T cells. When a nuclease cleaves the insert that disrupts 
eGFP ​, some NHEJ-induced indels place the mCherry in frame, inducing red fluorescence. By 
contrast, if an ​eGFP ​ HDR donor is supplied and used by the cell, the disrupted ​eGFP ​is 
repaired, inducing green fluorescence. We cloned an ​eGFP​ donor and an ​eGFP​-insert-specific 
Nme2Cas9 sgRNA into the rAAV:HDR constructs to enable HDR to restore eGFP expression; in 
designs C and D, we also included sgRNA target sites flanking the donor. Our flow cytometry 
analyses show that design D resulted in eGFP signals that were comparable to those induced 
by the use of a separate linear donor (generated by PCR) (Fig. 3b). We chose design D and its 
non-self-inactivating analog (design B) (Supplementary Note) for ​in vivo​ testing and validation. 
In vivo ​ validation of rAAV:HDR vectors in HT-I mice. ​To examine the therapeutic potential of 
our all-in-one rAAV:HDR systems, we designed two vectors: rAAV:HDR:uncleaved (from design 
B) and the self-eliminating rAAV:HDR:cleaved (from design D) (Fig. 3a). For these studies we 
used HT-I mice that contain a point mutation in the last nt of exon 8 of the ​Fah​ gene ​66​ (​Fah ​PM/PM​), 
leading to exon skipping that disables expression of the FAH protein ​82​.  Both vector designs 
contain Nme2Cas9, sgRNA targeting ​Fah​, and a 358bp HDR donor (including homology arms) 
to correct the G-to-A point mutation in ​Fah​ exon 8 in HT-I ​Fah​PM/PM​ ​mice. The HDR donor 
sequence also included PAM mutations (CC > TT, within intron 8) at the target site to prevent 
cleavage of the donor fragment or of the HDR-repaired ​Fah​ locus. In addition, we created a 
negative control vector expressing an sgRNA with a non-cognate spacer sequence 
(rAAV:FahDonor:ncSpacer) and another with a non-cognate donor (rAAV:ncDonor:FahSpacer) 
(Fig. 4a). Neither of these negative control vectors is capable of self-targeting. These four 
~4.8-kb vectors were packaged by the triple transfection method for rAAV8 packaging ​64​. 
Packaging of the rAAV:HDR:cleaved vector was modified to include a fourth plasmid expressing 
AcrIIC4 ​Hpa​ ​to prevent the self-elimination of the rAAV:HDR:cleaved plasmid during production 
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(Fig. 3c). 
For ​in vivo​ evaluation, 8 x 10 ​11​ gc of each vector was injected into adult HT-I ​Fah​PM/PM​ ​mice via 
tail vein. Mice were maintained on NTBC for five weeks and then monitored for body weight loss 
after NTBC withdrawal (Fig. 4b). Mice injected with PBS, rAAV:FahDonor:ncSpacer, or 
rAAV:ncDonor:FahSpacer showed the expected gradual body weight loss and were euthanized. 
Strikingly, cohorts injected with rAAV:HDR:uncleaved and rAAV:HDR:cleaved initially lost 
weight, but recovered and stayed healthy for 41 days (Fig. 4c). Some mice in the 
rAAV:HDR:cleaved and -uncleaved cohorts were put on NTBC-containing water temporarily to 
promote initial recovery. 
To determine the efficiency of genome editing, we performed targeted deep sequencing 
analysis to measure the level of genome modification at the ​Fah ​locus. HDR efficiency, 
calculated by co-conversion of all three edited positions [A..CC to G..TT], in pre-NTBC cohorts 
was very low (<0.1%); accurate quantifications were difficult to attain because of the inherent 
error rate of NGS, as well as the polyploid nature of hepatocytes and the presence of DNA from 
other nonparenchymal cells that are not efficiently transduced by AAV8 ​82​. HDR-edited reads 
were significantly increased to 4.4 ± 0.9% and 4.7 ± 0.4% in the rAAV:HDR:uncleaved and 
rAAV:HDR:cleaved cohorts, respectively 6 weeks after NTBC withdrawal. The relative increase 
over apparent editing efficiency in the wildtype cohort was likely due to the selective growth 
advantage of the successfully edited ​Fah​+​ cells after NTBC withdrawal (Fig. 4d; Supplementary 
Fig. 3). 
We also performed immunohistochemistry analyses of liver tissues to examine the extent of liver 
recovery by FAH protein expression. Before drug withdrawal, we detected a marked increase in 
the number of FAH​+​ cells in both rAAV:HDR cohorts (Fig. 4e; Supplementary 4). Interestingly, 
we observed through amplicon sequencing analysis that there were sporadic FAH​+​ cells in mice 
injected with rAAV:ncDonor:FahSpacer as a result of mutations that likely result from NHEJ 
repair events at the adjacent Nme2Cas9-catalyzed DSB (Supplementary Fig. 4).  Additionally, 
those cells were likely expanded after NTBC withdrawal, as the starting population was 
apparently insufficient to allow the mice to recover from the disease phenotype in the absence 
of NTBC augmentation (Fig. 4e; Supplementary Fig. 4). A greater number of corrected FAH​+ 
cells were observed in the rAAV:HDR cohorts before drug withdrawal, supporting eventual 
recovery (Fig. 4e; Supplementary Fig. 4). mRNA sequencing analyses showed that effective 
gene repair post-NTBC withdrawal was associated with significant increases in the level of ​Fah 
mRNA in both rAAV:HDR cohorts (relative to PBS, ncDonor, and ncSpacer controls, Fig. 4f and 
Supplementary Fig. 3). RT-PCR analysis with primers spanning exons 5 to 9 of ​Fah​ showed that 
the increased levels of ​Fah ​mRNA is also associated with exon 8 inclusion (Supplementary Fig. 
3). 
As expected by body weights, editing efficiencies, and FAH expression, HT-I mice treated with 
rAAV:HDR vectors exhibited striking reductions in liver damage as indicated by the significant 
reduction in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
levels (Fig. 4g,h), as well as normalization of hepatocyte histology (Supplementary Fig. 3). 
Globally, 8,827 and 8,170 genes were differentially expressed in HT-I mice treated with 
rAAV:HDR:uncleaved and rAAV:HDR:cleaved vectors, respectively (FDR <= 5%, relative to 
treatment with rAAV:HDR:ncDonor:FahSpacer vector; Supplementary Fig. 3). Differentially 
expressed genes were enriched among gene ontology categories involved in small molecule 
metabolic processes (Supplementary Table). Only four genes were significantly differentially 
8 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted October 9, 2020. . https://doi.org/10.1101/2020.10.09.333997doi: bioRxiv preprint 
 
expressed between the rAAV:HDR:uncleaved and rAAV:HDR:cleaved vector treatments (FDR 
<= 5%, Supplementary Fig. 3), indicating similar targeting ability between the two vectors.  
Previous efforts to create self-targeting rAAV:Cas9 vectors involved dual-vector systems​77,83​. 
Our all-in-one system necessarily involves co-expression of Nme2Cas9 and sgRNA in the same 
cell, enabling the targeting of engineered sites flanking the ​Fah​ HDR donor (Fig. 4a). 
Quantitative PCR was used to examine the number of rAAV genome copies in mice and 
suggested that liver samples from animals treated with the rAAV:HDR:cleaved vector contained 
significantly lower rAAV copies than the rAAV:HDR:uncleaved mouse cohorts after NTBC 
withdrawal (Supplementary Fig. 5). This reduction in rAAV episomal numbers was not 
associated with a significant decrease in steady-state levels of Nme2Cas9 mRNA as measured 
by mRNA sequencing (Supplementary Fig. 5). However, total Nme2Cas9 mRNA and sgRNA 
transcripts decreased over time, as measured by quantitative RT-PCR with random hexamer 
primers capturing both nascent and mature mRNAs, suggesting that the AAV:HDR:cleaved 
platform can reduce the unwanted long-term expression of Nme2Cas9 (Supplementary Fig. 5).  
Additionally, we observed that the detected level of rAAV fragments integrated at the Cas9 DSB 
Fah​ site is significantly lower in the rAAV:HDR:cleaved cohort compared to 
rAAV:HDR:uncleaved (Supplementary Fig. 5). All of these data suggest that the self-eliminating 
rAAV:HDR:cleaved vector is a more therapeutically viable option, as it can function ​in vivo​ to 
repair DNA mutations, while eliminating rAAV genomes and Nme2Cas9 expression over time. 
In vivo ​ validation of rAAV:HDR vectors in MPS-I mice. ​The selective expansion of correctly 
edited cells in HT-I mice enabled therapeutic benefit even when editing efficiencies were very 
low. We sought a second disease model in which editing is not known to induce selective clonal 
expansion, to determine whether HDR efficiencies with our all-in-one rAAV system could still 
reach therapeutic thresholds. We chose MPS-I mice, which suffer from an accumulation of 
glycosaminoglycans (GAGs) in lysosomes. These mice carry a G-to-A mutation in the gene 
encoding the α-L-iduronidase (IDUA) enzyme, converting the Trp392 codon into a stop codon. 
Previous reports showed that IDUA enzyme activity as low as 0.2% of normal levels can provide 
therapeutic benefit in MPS-I patients​84​, largely due to uptake of secreted IDUA by uncorrected 
cells. We engineered two ​Idua​-targeting vectors analogous to those used above 
(rAAV:HDR:uncleaved and rAAV:HDR:cleaved) containing Nme2Cas9, an sgRNA targeting 
Idua​, and a 272-bp donor (including homology arms) to correct the disease-causing G-to-A point 
mutation. Because the pathogenic mutation resides within an exonic protein-coding sequence, a 
PAM mutation is not feasible without altering the amino acid sequence. As an alternative 
approach, we incorporated two silent mutations (A..C > G..T) in the seed sequence of the 
spacer to prevent cleavage of the donor (Fig. 5a). Re-targeting of the edited allele by 
Nme2Cas9 would be further inhibited by the third non-complementary seed residue at the 
HDR-corrected position. For the negative control vector, we generated an rAAV backbone 
analogous to rAAV:HDR:uncleaved, but containing a non-cognate sgRNA spacer 
(rAAV:IduaDonor:ncSpacer) (Fig. 5a). All three vectors were packaged into AAV9 capsids, and 
cohorts of neonate MPS-I mice were injected with 4 x 10 ​11​ gc of each vector via facial vein (Fig. 
5b). Liver tissue lysates were collected and IDUA enzymatic activities were measured. We 
observed significant increases in IDUA activity to 3.0 ± 0.03% and 2.3 ± 0.2% of wild-type levels 
in rAAV:HDR:uncleaved and rAAV:HDR:cleaved cohorts, respectively (Fig. 5c). This increase 
was above the therapeutic threshold required for effective reduction of GAG accumulation in the 
liver (Fig. 5d). Targeted amplicon sequencing analysis of total liver DNA​ ​confirmed the corrected 
"G--T-G" pattern at the ​Idua ​locus in rAAV:HDR:uncleaved (4.5 ± 0.49%) and 
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rAAV:HDR:cleaved (3.3 ± 0.43%) cohorts (Fig. 5e). Via qRT-PCR assays we also observed 
significant increases in ​Idua​ mRNA in the liver (Fig. 5f), likely due to reductions in 
nonsense-mediated mRNA decay of the edited transcripts. Other organs exhibited lower but 
notable levels of HDR (Fig. 5e). 
To examine the self-cleaving ability of rAAV:HDR:cleaved vectors, quantitative PCR assays 
were designed using four primer pairs, including two that span the ends of the donor (where the 
cleavage sites reside in the self-targeting version) (Supplementary Fig. 6). Unlike 
rAAV:HDR:uncleaved cohorts, mice injected with the rAAV:HDR:cleaved vector had significantly 
lower qPCR signals in the liver (Fig. 5g). The frequency of rAAV fragment integration at the ​Idua 
target site (as detected by NGS sequencing) was minimal, with significantly fewer insertion 
events detected with the rAAV:HDR:cleaved vector (Supplementary Fig. 6). Nme2Cas9 mRNA 
and sgRNA transcripts were modestly reduced, as measured by qRT-PCR (Supplementary Fig. 
6). Since these mice were injected as neonates, Nme2Cas9-specific humoral immune 
responses did not develop in MPS-I mice, while adult-treated HT-I and healthy C57BL/6 mice 
treated with rAAV:Nme2Cas9 targeting the ​Rosa26 ​locus​24​ generated readily detectable 
α-Nme2Cas9 IgG1 antibodies with no apparent difference between rAAV:HDR:cleaved and 
rAAV:HDR:uncleaved cohorts (Supplementary Fig. 6). In conclusion, rAAV:HDR vectors have 
the potential to correct inherited disease mutations ​in vivo​, while enabling the therapeutic 
benefits of longer-term self-elimination to minimize genotoxic and off-target effects, as well as 
possible cellular immune responses against transduced tissues. 
 
Discussion 
The tremendous potential of precision genome editing ​in vivo​ to repair pathogenic mutations still 
faces significant translational hurdles. AAV vectors for Cas9 genome editing exhibit great 
promise for some tissues and are already in clinical trials for NHEJ-based edits 
(ClinicalTrials.gov; identifier: NCT03872479). However, rAAV delivery systems for precise 
genomic re-writing via HDR or base editing have required multiple vectors​38–45​. The extreme 
rAAV dosages needed for multi-vector strategies impose safety difficulties in clinical 
applications​46–48​. Here, we have developed single-vector systems with standard rAAV serotypes 
and cargo limits for precise Nme2Cas9 editing via HDR. Nme2Cas9 is well-suited for this 
strategy because it is compact, active in adult mammals ​in vivo​, highly accurate within 
eukaryotic cells, and has a broad targeting range due to its modest (dinucleotide) PAM 
requirement​24,50​. We further employed an Acr protein during cloning and vector production to 
enable the inclusion of self-targeting sites that can facilitate vector self-elimination over time, 
once the Nme2Cas9/sgRNA complex has accumulated to functional levels. The use of Acr 
proteins to protect otherwise self-inactivating genome editing vectors was reported previously 
for adenovirus vectors​85​ but to our knowledge has not been described for the more commonly 
employed rAAV. The ever-expanding roster of anti-CRISPRs against different genome editing 
effectors​51,52​ suggests that this strategy will be useful far beyond Nme2Cas9. We validated our 
all-in-one rAAV HDR platform ​in vivo​ in two disease models in mice (HT-I and MPS-I), and in 
both cases editing efficiencies reached therapeutic thresholds. Our ability to fit an HDR donor 
into a single-vector system along with Nme2Cas9-NLS and sgRNA transgenes was enabled by 
minimizing the latter components and their regulatory elements. We also generated all-in-one 
vectors encoding two guides, and demonstrated that this dual-sgRNA all-in-one system was 
effective ​in vivo​ for inducing segmental deletions in HT-I mice. In the latter case, sgRNA 
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cassette placement and orientation was a critical factor in vector packaging efficiency. The two 
successful designs involved precise targeting of sgRNAs to exon boundaries, resulting in an 
unexpected diversification of ​Hpd​ mRNA splicing events through unknown mechanisms that 
merit further study.  
Although therapeutic thresholds were reached by the all-in-one HDR system ​in vivo​ for the two 
preclinical disease models that we tested, HDR efficiencies were nonetheless low in absolute 
terms. This is not particularly surprising because of several factors: (​i​) the lengths of the 
homology arms needed for HDR are constrained by rAAV vector cargo limits; (​ii​) donor DNA 
cannot be delivered in excess of guide- and effector-expressing vector; (​iii​) many mammalian 
cells and tissues ​in vivo​ are quiescent or terminally differentiated, leading to a general loss of 
HDR capacity​16​. In its current form, our single-AAV-vector HDR approach would therefore be 
limited to applications where successfully edited cells have a proliferation advantage (as with 
HT-I), or where low levels of correction suffice for clinical benefit (as with MPS-I). Nonetheless, 
in such cases, the reduction in vector dose permitted by the use of a single-vector system could 
be crucial for the safety profile of precision therapeutic editing. A previous report also described 
an all-in-one rAAV system for HDR-based editing and applied it to HT-I mice ​49​. However, this 
method used a VP2-deleted capsid system that enabled larger cargoes (>5 kb) but appeared to 
package inefficiently​49​. We report here that standard rAAV vector platforms that accommodate 
<4.9 kb genomes can be used for single-vector HDR ​in vivo​.  
In addition to reductions in vector dose, safety prospects are also potentially improved by our 
system’s implementation of self-cleavage ability, enabled by anti-CRISPR inhibition of Cas9 
activity during cloning and packaging. Our qPCR assays suggest modest degrees of rAAV 
genome depletion over a 5- to 11-week editing regimens. Whether self-elimination increases 
over longer time courses will require more extended follow-up studies. We did not observe 
detectable increases in vector fragment insertion into the chromosomal target site with the 
self-inactivating vector. We designed our self-targeting system to have the added benefit of 
generating a linear HDR donor, in part to test the hypothesis that such a configuration would 
improve HDR efficiency over that of the uncleaved HDR vector. We obtained no clear evidence 
that donor excision capacity improves HDR frequencies ​in vivo​, though the potential long-term 
benefits of vector elimination still apply, even if HDR enhancement via donor cleavage cannot 
be detected in other physiological contexts in the future.  
In conclusion, we have developed and validated new viral delivery platforms for ​in vivo ​genome 
editing that enable precision editing via HDR, using single-vector systems that are compatible 
with well-characterized rAAV backbones and serotypes. We have further developed the means 
to enable cloning, packaging, and use of rAAV vectors endowed with self-targeting capabilities. 
These systems improve the balance between the competing imperatives of improving vector 
capabilities (e.g. enabling precise editing via HDR) and limiting vector dose to maximize safety, 
reduce cost, and mitigate production bottlenecks. As additional routes toward increased HDR 
emerge in the future, this could enable single-vector HDR-based rAAV delivery systems to 
address clinical indications that demand higher levels of precise gene correction, perhaps 
including those that are difficult or impossible to achieve via base editing or prime editing. 
 
Methods 
Hereditary Tyrosinemia type I mice​. All animal study procedures were approved by the 
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Institutional Animal Care and Use Committee (IACUC) at the University of Massachusetts 
Medical School. HT-I mice were kindly provided by Dr. M. Grompe and maintained on C57 
background for the ​Fah​PM/PM​ strain, and on ​a 129 background ​ for ​Fah​neo/neo​. Mice were kept on 
10 mg/L ​2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC; Sigma-Aldrich, Cat. 
No. PHR1731-1G) in drinking ​water when indicated. Male and female mice (8 to 15 weeks old) 
were used, and their body weights were recorded every 1-3 days. M​oribund m​ice with more 
than 10% body weight loss were humanely euthanized, and sera and liver tissues were 
harvested for genome editing analyses. Tissues were pulverized in liquid nitrogen and aliquots 
of tissue powder (~30 mg) were used to extract total DNA [using the DNeasy Blood and Tissue 
Kit (Qiagen), according to the manufacturer’s protocol], as well as total RNA and total protein. 
Mucopolysaccharidosis type I mice. ​Homozygous MPS-I ​Idua​W392X​ mice ​86​ were purchased 
from the Jackson Laboratory (Stock No. 017681) and used to breed neonatal ​Idua​W392X​ pups for 
rAAV injections. Postnatal day 1 mice were injected with 4 x 10 ​11​ gc of rAAV:HDR:uncleaved, 
rAAV:HDR:cleaved, or control vectors via facial vein. Five weeks after injection, blood was 
collected via cardiac punch, and mice were transcardially perfused with ice-cold PBS. Tissues 
were immediately dissected, snap-frozen in liquid nitrogen, and stored at -80°C. Both female 
and male animals were used. All animal procedures were reviewed and approved by the IACUC 
at University of Massachusetts Medical School and performed in compliance with all relevant 
ethical regulations. 
Cloning of rAAV plasmids ​. All rAAV vectors were based on our previously published rAAV 
plasmid [Nme2Cas9_AAV; Addgene plasmid #119924] design ​24​, with modifications to increase 
the cargo capacity (​Supplementary​ Fig. 1). Human-codon-optimized ​Neisseria meningitidis 
DE10444 Cas9 (Nme2Cas9) is under the expression of a ​U1a​ promoter, with one SV40 nuclear 
localization signal (NLS) on the N terminus and one nucleoplasmin NLS on the C terminus, 
followed by a short poly(A) signal ​56​. Shortened single-guide RNA Nme.sgRNA-121 was 
synthesized as a gblock for cloning. Target spacer sequences were inserted by digesting the 
plasmid with BspQI restriction enzyme, and the annealed spacer sequence carrying appropriate 
BspQI overhang sequences were ligated. This plasmid is available on Addgene (pEJS1089: 
mini-AAV:sgRNA.Nme2Cas9; Addgene # 159536). 
Cloning of Dual-guide rAAV:Nme2Cas9 plasmids. ​A second human ​U6​ promoter with an 
Nme.sgRNA-121 expression cassette was generated as a gblock (IDT) and cloned into the 
minimized rAAV:Nme2Cas9 plasmid to create dual-sgRNA designs 1-4 (Fig. 1a). The two 
configurations that enabled efficient packaging of full-length vector genomes (designs 1 and 4) 
are available on Addgene (pEJS1099: Dual-sgRNA:Design 4, Addgene #159537; ​pEJS1096: 
Dual-sgRNA:Design 1, Addgene # 159538)​. Oligonucleotides with spacer sequences for target 
genes were inserted into the sgRNA cassette by ligation into the BspQI and BsmBI cloning 
sites.  
Cloning of rAAV:HDR plasmids. ​Donor DNA fragments with target sites (AAV:HDR:cleaved) 
or without target sites (rAAV:HDR:uncleaved) were synthesized as gblocks (IDT) and cloned 
into the minimized Nme2Cas9+sgRNA AAV backbone plasmid following digestion of the latter 
with SalI restriction enzyme. The rAAV:HDR:uncleaved plasmids were cloned in NEB 5-alpha 
Competent ​E. coli​ cells (Catalog # C2987H), while rAAV:HDR:cleaved plasmids were cloned 
into the ​ ​DH5α-AcrIIC4 ​Hpa ​E. coli​ strain that we constructed ​. ​Oligonucleotides with spacer 
sequences for target genes were inserted into the sgRNA cassette by ligation into the BspQI 
cloning sites. 
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Creating ​E. coli ​ DH5 cells stably expressing anti-CRISPR protein DH5α-AcrIIC4​Hpa​. Cells 
were created by λRed-promoted PCR-mediated recombination as previously described ​78​. 
Briefly, ​acrIIc4 ​Hpa​, its promoter and Kan ​
R​ cassette were cloned from plasmid 
pUC57mini-AcrIIC4 ​Hpa​ (generously provided by Dr. Alan Davidson’s lab at the University of 
Toronto) into the pKIKOarsBKm (Addgene #46766) plasmid by restriction digestion and ligation 
into the ​arsB ​locus of DH5α. Cells harboring plasmid pKM208 (Addgene #13077) were cultured 
at 30˚C to an O.D. of 0.35, induced with 1 mM IPTG, and harvested at an O.D. of 0.80. Cells 
were prepared for electroporation (washing with 10% glycerol) and transformed with 500 ng of 
gel-purified PCR product (​acrIIc4​Hpa​, its promoter and Kan ​
R​). After incubation at 37˚C overnight 
in kan-LB media, colonies were screened by PCR for the ​acr ​gene and the expected junction of 
the recombineered product with the ​arsB ​gene. Correct clones were passaged at 42˚C to 
eliminate the pKM208 plasmid. 
The rAAV:HDR:cleaved plasmids were linearized with BspQI restriction enzyme and spacer 
sequences with compatible overhangs were ligated into 100 ng of plasmid backbone using 
ElectroLigase® (NEB M0369) following the manufacturer’s protocol. For electro-transformation, 
2 μL of ligation reaction was added to 40 μL of DH5α-AcrIIC4 ​Hpa​ ​E. coli ​ and electroporated at 
2500 V, 200 Ω, 25 μF, in a 2 mm gap cuvette using Gene Pulser Xcell Electroporation Systems 
[Bio-Rad #1652660]. 
Vector production ​ Packaging of AAV vectors was done at the Viral Vector Core of the Horae 
Gene Therapy Center at the University of Massachusetts Medical School as described 
previously​64​. Constructs for HT-I studies were packaged in AAV8 capsids, whereas constructs 
for MPS-I studies were packaged in AAV9 capsids. A plasmid expressing anti-CRISPR protein 
(pEJS581; pCSDest2-AcrIIC4 ​Hpa​-FLAG-NLS; Addgene # 113436) was included in the 
triple-transfection packaging process to maintain intact rAAV:HDR:cleaved plasmids during 
production. Vector titers were determined by droplet digital PCR, and by gel electrophoresis 
followed by silver staining. 
Cell culture. ​HEK293T cells harboring ​ ​Traffic Light Reporter Multi-Cas Variant 1 (TLR-MCV1)​81​, 
as well as Neuro2a cells (ATCC CCL-131), were cultured in Dulbecco’s Modified Eagle Media 
(DMEM, Thermo Fisher Scientific, Cat. No. 11965084); while MOLT-3 cells were cultured in 
RPMI-1640 medium. Both media were supplemented with 10% FBS (Thermo Fisher Scientific, 
Cat. No. 10438034) and 1% Penicillin/Streptomycin (GIBCO). Cells were incubated at a 37°C 
incubator with 5% CO​2​. 
Plasmid transfection. ​HEK293T cells and TLR-MCV1 cells were transfected using PolyFect 
Transfection Reagent (Qiagen, Cat No. 301105) with 400 ng of plasmid in a 24-well plate 
according to the manufacturer’s protocol. Neuro2a cells were transfected with 1000 ng of 
plasmid using Lipofectamine 3000 Reagent (Thermo Fisher Scientific, Cat. No. L3000015) 
following the manufacturer’s protocol. FACS analysis for the TLR-MCV1 cells were performed 3 
days post-transfection using a Miltenyi MACSQuant VYB flow cytometer. HEK293T and 
Neuro2a cells were harvested 3 days post-transfection and genomic DNA was extracted using a 
DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer’s protocol. 
Ribonucleoprotein nucleofection. ​Nme2Cas9 protein was expressed in Rosetta (DE3) cells 
and purified using a Ni ​2+​-NTA agarose column (QIAGEN) as previously described ​24​. Wild-type 
(wt) gRNA was in vitro transcribed using the HiScribe T7 High Yield RNA Synthesis Kit (New 
England Biolabs) according to the manufacturer’s protocol. Truncated guide (Nme.sgRNA-100) 
was chemically modified with 2'-​O​-methyl analogs and 3'-phosphorothioates in 5' and 3' terminal 
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RNA residues, and was synthesized by Synthego (Redwood City, CA, USA). RNP complex was 
electroporated into HEK293T or MOLT-3 cells using the Neon transfection system. Briefly, 40 
picomoles (HEK293T and MOLT-3 cells) of 3xNLS-Nme2Cas9 and 50 picomoles (HEK293T 
and MOLT-3 cells) of T7-transcribed or chemically synthesized sgRNA was assembled in buffer 
R along with 100,000 HEK293T cells or 200,000 MOLT-3 cells and electroporated using 10 μL 
tips. Electroporation parameters (voltage, width, number of pulses) were 1150 V, 20 ms, 2 
pulses for HEK293T cells; 1600 V, 10 ms, 3 pulses for MOLT-3 cells.  
TIDE analysis, amplicon sequencing and indel analysis ​. PCR was carried out with TIDE or 
amplicon sequencing primers as shown in the Supplementary Table using High Fidelity 2x PCR 
Master Mix (New England Biolabs). PCR products were purified using the DNA Clean & 
Concentrator-100 (Zymo, Cat. No. D4029) and sent for Sanger sequencing using a TIDE 
forward primer (Supplementary Table). Indel readouts were obtained using the TIDE web tool 
(https://tide-calculator.nki.nl/) as previously described ​27​. For amplicon sequencing, PCR was 
carried out using amplicon sequencing primers shown in the Supplementary Table. Equimolar 
amounts of DNA were amplified with a universal forward primer and an indexed reverse primer 
(98 °C, 15 s; 61 °C, 25 s; 72 °C, 18 s; nine cycles) to ligate the TruSeq adaptors. The resultant 
amplicons were purified using Ampure beads. Libraries were sequenced for 600 cycles 
(300/300 PE) on a MiSeq  (​Fah​ locus), and for 300 cycles (SE) on a MiniSeq (​Idua​ locus). 
FASTQ files were analyzed using CRISPResso2 with parameters specifying guide, amplicon 
and expected HDR sequences. A no-guide sample was used as the negative control to 
determine background. AAV integration was quantified as previously described ​87​ using 
BWA-MEM and ​samtools​ to align sequenced amplicons files to the ​Idua​ locus and AAV vector 
sequence. 
SMRT sequencing ​. Amplicon libraries were constructed using locus-specific primers as shown 
in the Supplementary Table using Q5® High-Fidelity DNA Polymerase (New England Biolabs). 
One primer of each pair contains an 8-nucleotide UMI and both contain adapter overhangs to 
multiplex the library using Bar. Univ. F/R Primers Plate-96v2 (Pacbio part no. 101-629-100). 
Forward and reverse primers were 1.1 kb and 1.9 kb from gRNA-I and gRNA-II Cas9 DSB sites, 
respectively. Each sample was amplified by linear amplification (98°C for 40 s, followed by 10 
cycles of 98 °C for 30 s, 64 °C for 20 s and 72°C for 75 s) using the forward primers. A second 
PCR amplification was performed using a universal PacBio primer and a gene-specific reverse 
primer at 98°C for 30 s, followed by 30 cycles of 98°C for 15 s, 64°C for 20 s and 72°C for 75 s, 
and extended at 72°C for 5 m. PCR products were diluted (1:100) and amplified using PacBio 
barcoded primers at 98°C for 30 s, followed by 30 cycles of 98°C for 15 s, 64°C for 20 s and 
72°C for 75 s, and extended at 72°C for 12 m. Equimolar amounts of the products were 
combined together and purified by AMPure PB beads (PacBio, part no. 100-265-900) following 
the manufacturer’s recommendation. The libraries were sequenced on an Pacific Biosciences 
Sequel II Instrument in a 10-hour collection SMRTCell ​TM​. Circular​ ​consensus sequence (ccs) 
reads generated by SMRT Link v8 using default parameters in fastq format were processed and 
analyzed using the Galaxy web platform at usegalaxy.org ​88​ with custom workflows, unless 
specified. Briefly, reads were demultiplexed using ​FASTQ/A Barcode Splitter,​ and converted to 
fasta to calculate and count read lengths within each library (Supplementary Fig. 2). To assign 
reads that represent segmental deletions, inversions, or indel events, reads were first re-IDed 
by appending each sequence identifier with the UMIs using fastp with (-U). Duplicated UMIs 
were removed from the analysis. Reads with mapping qualities >20 were then uniquely aligned 
using BWA-MEM to reference sequences representing the wild-type loci and the predicted 
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sequences following segmental deletion or inversion. The counts for reads aligning to the 
specified references were displayed as a percentage of all mapped reads. To categorize reads 
that mapped to the wild-type reference as either bearing indel events or unedited genomes at 
indicated target loci, reads were trimmed to ±100 nt surrounding each target PAM by ​Cutadapt​. 
Trimmed reads were then converted to fasta and clustered by ​UCLUST​89​, a centroid-based 
clustering algorithm.  Singlets were discarded and treated as reads bearing sequencing errors. 
Clustered reads using size reporting (-sizeout) were categorized into unedited and edited 
groups at each target site or both sites for dual-guide vectors and displayed as a percentage of 
all reads mapping to the respective wild-type sequence. To assess target loci that harbor vector 
genome integration events, fastq reads were mapped to the relevant vector genome reference 
and expressed as a percentage of all reads.  
RNA sequencing​.  Total RNA was isolated from liver tissues using TRIzol reagent and 
separated by chloroform. RNA-seq library preparation was performed with 1ug of total RNA per 
sample using the TruSeq Stranded mRNA Library prep kit (Illumina, 20020595) following the 
manufacturer’s protocol. Libraries were made for the following mice: 3 PBS treated ​Fah​neo/neo​, 8 
dual-sgRNA Design 1 treated ​Fah​neo/neo​, 8 dual-sgRNA Design 4 treated ​Fah​neo/neo​, 3 healthy 
C57BL/6, 4 dual-sgRNA Design 1 treated C57BL/6, 4 dual-sgRNA Design 4 treated C57BL/6, 3 
PBS treated ​Fah​PM/PM​, 3 rAAV:HDR:FahDonor:ncSpacer treated ​Fah​PM/PM​, 3 
rAAV:HDR:ncDonor:FahSpacer treated ​Fah​PM/PM​, 10 rAAV:HDR:uncleaved treated ​Fah​PM/PM​, and 
10 rAAV:HDR:cleaved treated ​ Fah​PM/PM​. Libraries were sequenced on an Illumina NextSeq 500 
with single-end 75 nucleotide reads and an average of 19.88 million reads. All downstream 
analyses were performed with the Ensembl GRCm38.p6 (GCA_000001635.8) ​Mus musculus 
genome adapted to include the Nme2Cas9 mRNA sequence. Transcripts Per Million (TPM) 
were calculated with alignment-free quantification using Kallisto v0.45.0. Reads were mapped to 
the mm10 genome using STAR v2.7.5a in chimeric mode to identify chimeric junction reads and 
HTSeq v.0.10.0 was used to quantify read counts for each gene. Differential expression 
analyses were performed with DESeq2 release 3.11 after filtering out genes with less than 10 
read counts across all samples in the comparison. Gene ontology analyses were conducted 
with a custom script to test for enrichment of functional annotations among significantly 
differentially expressed genes, in order to avoid significant gene ontology terms with overlapping 
gene sets. Specifically, the script uses gene ontology annotation databases from the Gene 
Ontology Consortium to perform iterative enrichment analyses and ​p​ values are computed using 
a Fisher-exact test and then corrected using an Benjamini-Hochberg multiple test correction. 
HPD western blotting. ​Liver tissue fractions were ground, resuspended in 200 μL of RIPA lysis 
buffer and allowed to lyse for 15 m on ice. Measurements of total protein content was 
determined by Pierce™ BCA Protein Assay Kit (Thermo-Scientific) following the manufacturer’s 
protocol. A total of 25 μg of protein was loaded onto a 4–20% Mini-PROTEAN® TGX™ Precast 
Gel (Bio-Rad) and transferred onto a PVDF membrane. After blocking with 5% Blocking-Grade 
Blocker solution (Bio-Rad) for 2 h at room temperature, membranes were incubated with rabbit 
anti-HPD (Sigma HPA038322, 1:600) overnight at 4 °C. Membranes were washed three times 
in TBST and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Bio-Rad 
1,706,515, 1:10,000) secondary antibodies for 2 h at room temperature. The membranes were 
washed four times in TBST and visualized with Clarity™ western ECL substrate (Bio-Rad) using 
a Bio-Rad ChemiDoc MP imaging system. Membranes were stripped using Restore™ Western 
Blot Stripping Buffer (Cat. number: 21059) following the manufacturer’s protocol and blocked 
with 5% Blocking-Grade Blocker solution (Bio-Rad) for 2 h at room temperature. The 
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membranes were incubated with rabbit anti-GAPDH (Abcam ab9485, 1:2,000)​ ​overnight at 4°C, 
washed three times in TBST, and incubated with HRP-conjugated goat anti-rabbit (1:4,000) 
secondary antibodies for 2 h at room temperature. The membranes were washed four times in 
TBST and visualized with Clarity™ western ECL substrate (Bio-Rad) as above. 
Histological analysis ​. Liver tissues were harvested, and sections were placed in biopsy 
cassettes and fixed in 10% buffered formalin overnight before changing into 70% ethanol 
solution. FAH immunohistochemistry (IHC) was performed using anti-FAH antibody (Abcam, 
Cat. No. ab81087; dilution 1:400), whereas HPD IHC was performed using anti-HPD antibody 
(​Sigma HPA038322; dilution 1:30)​. IHC and hematoxylin and eosin (H&E) staining were 
performed by the Morphology Core at University of Massachusetts Medical School following 
standard procedures. 
Reverse transcription PCR​. Total RNA was isolated from liver tissues using TRIzol reagent 
and separated by chloroform. Reverse transcription reactions were carried out using 
SuperScript™ III First-Strand Synthesis System (Thermo Fisher Scientific; 18080051) following 
the manufacturer's protocol. The complementary DNA was used to quantify ​Fah​ gene 
expression in a qPCR reaction using primers shown in the Supplementary Table using PowerUp 
SYBR Green Master Mix (Applied Biosystems, Cat. No. A25742). All reactions were normalized 
to ​gapdh​ and relative quantification in gene expression was determined using the 2 ​- ΔΔCt​ method. 
PCR products were resolved by agarose gel electrophoresis. 
Quantitative PCR for rAAV copy number ​. Genomic DNA from mouse tissue was used to 
quantify rAAV copy number using primers shown in the Supplementary Table using PowerUp 
SYBR Green Master Mix (Applied Biosystems, Cat. No. A25742). All reactions were normalized 
to ​gapdh ​control and relative quantification of rAAV copies was determined using the 2 ​- ΔΔCt 
method relative to PBS-injected cohorts. 
Serum aspartate transaminase (AST) and alanine transaminase (ALT) assays​. Blood was 
collected from mice by cardiac puncture immediately before euthanasia, and sera were isolated 
using a serum separator (BD, Cat. No. 365967) and stored at -80°C. AST and ALT levels were 
determined using Cobas Clinical Chemistry Analyzer at the MMPC-University of Massachusetts 
Medical School Analytical Core (RRID:SCR_015365). Two mice in the PBS- and 
rAAV:ncDonor:FahSpacer negative control HT-I cohorts were ​hemolyzed, so we were able to 
measure ALT/AST for only one mouse. ​In the rest of the groups, data are presented as mean 
values ± s.e.m. (n = 3-7 mice per group). 
Iduronidase activity assay​. The iduronidase activity assay was performed as described 
previously​86,90,91​ with minor modifications. Tissues were homogenized in ice-cold T-PER protein 
extraction reagent (Thermo Fisher Scientific, Cat. No. 78510) with protease inhibitor (Roche, 
Cat. No. 4693159001) using TissueLyser II (Qiagen). Quantification of total protein 
concentration was assessed by the bicinchoninic acid (BCA) method (Pierce, Cat. No. 23225). 
No more than 80 μg of total protein was used in enzymatic reactions (100 μL of total reaction 
volume), which includes sodium formate buffer, pH 3.5 (130 mM), D-saccharic acid 1,4-lactone 
monohydrate (0.42 mg/mL, Sigma-Aldrich, Cat. No. S0375), and 4MU-iduronic acid (0.12 mM, 
Santa Cruz Biotechnology, Cat. No. sc-220961). The reaction was incubated under 37°C for 
24-48 h, and quenched with glycine buffer (pH 10.8). The fluorescence of released 4MU 
(excitation wavelength: 365 nm; emission wavelength: 450 nm) was detected using a 
fluorescence plate reader (BioTek) and compared against a standard curve generated using 
4MU (Sigma-Aldrich, Cat. No. M1381). The iduronidase specific activity was calculated as 4MU 
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released (pmole) per milligram of total protein per hour. 
Glycosaminoglycan (GAG) assay. ​The glycosaminoglycan (GAG) assay was performed using 
a protocol previously described ​91​. Tissues were homogenized in a mixture of chloroform and 
methanol (2:1) using TissueLyser II (Qiagen) and dried in a Vacufuge (Eppendorf) to remove 
fat. The dried and defatted tissue was weighed and digested using papain (Sigma-Aldrich, Cat. 
No. P3125) at 60°C overnight. The supernatant was used in the Blyscan assay to quantify GAG 
content using chondroitin-4-sulfate as standard (Accurate Chemical, Cat. No. CLRB1000). 
Levels of GAG were calculated as GAGs (microgram) per milligram of dried, defatted tissue. 
Humoral ​α- ​Nme2Cas9 immune response. ​Nme2Cas9-specific humoral immune response 
was measured as previously described ​27​. Briefly, a ​96-well plate (Corning) was coated with 0.5 
μg of recombinant Nme2Cas9 protein suspended in 1× coating buffer (Bethyl E107). The plate 
was incubated for 12 h at 4°C with shaking, then washed three times using 1x Wash Buffer 
(Bethyl E106). The plate was blocked with blocking buffer (Bethyl E104) for 2 h at room 
temperature. After washing three times, diluted sera (1:40 in dilution buffer consisting of 1L of 
TBS, 10 g of BSA and 5 mL of 10% Tween 20) from mice injected with rAAV:Nme2Cas9 were 
added to each well in duplicates and incubated at 4°C for 6 h. The plate was washed three 
times, and goat anti-mouse HRP-conjugated antibody (100 μL; 1:100,000 dilution; Bethyl 
A90-105P) was added to each well. The plates were incubated at room temperature for 1 h, 
then washed four times. To detect immune response, the plate was developed by adding 100 
μL of TMB One Component HRP Substrate (Bethyl E102). After incubating in the dark for 30 m 
at room temperature, Stop Solution (Bethyl E115; 100 μL per well) was directly added. 
Absorbance was measured at 450 nm using a BioTek Synergy HT microplate reader. 
Statistical analysis​. All data are presented as mean values ± s.e.m. ​p​ values are calculated 
using Student’s t-test (2-sided) and one-way ANOVA using GraphPad Prism. 
Reporting Summary​. Further information on research design is available in the Nature 
Research Reporting Summary linked to this article. 
 
Data availability 




All analysis was performed using publicly available programs and the parameters indicated in 
the Methods section. 
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Fig. 1 | In vitro validation of dual-sgRNA AAV:Nme2Cas9 plasmids. a, Schematic of four different 
designs of dual-sgRNA AAV:Nme2Cas9 vector plasmids containing two sgRNA expression cassettes. b, 
Alkaline agarose gel electrophoresis of viral DNA isolated from the four dual-sgRNA AAV:Nme2Cas9 
vectors presented in (a) after packaging in AAV8. DNA size markers are indicated. Red arrows indicate full-
length non-truncated viral genomes. c, Schematic diagram of the mouse Hpd gene. The first target site is 
represented by half arrowhead in red (gRNA-I) and the second target site is represented in green (gRNA-II). 
SMRT sequencing primers are also highlighted in gray. d, Stacked histograms displaying the percentages 
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of segmental deletion (orange) and inversion (blue) outcomes following gene editing after plasmid 
transfection of dual-sgRNA:Designs 1 and 4 plasmids in Neuro2a cells, as measured by SMRT sequencing 
analysis. e, Stacked histograms displaying the percentages of indels detected in full-length SMRT 
sequencing reads after Hpd editing by plasmid transfection in Neuro2a cells. The graph indicates genome 
reads with indels recorded only at gRNA-I (in red), indels only at gRNA-II in (dark green), and indels at both 
gRNA-I and gRNA-II (yellow) as measured by SMRT sequence analysis. Data are presented as mean 
values ± s.e.m. (n = 2  biological replicates). 
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Fig. 2 | In vivo gene editing using dual-sgRNA rAAV:Nme2Cas9 vectors. a, In vivo experimental plan 
to validate rAAV:Nme2Cas9 Dual-sgRNA:Designs 1 and 4 to disrupt the Hpd gene by tail vein injections of  
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AAV8 vectors in adult Fahneo/neo and C57BL/6 mice. b, Complete rescue of body weights after Dual-
sgRNA:Designs 1 and 4 in Fahneo/neo mice. c, Quantification of editing events in C57BL/6 (left) and 
Fahneo/neo (right) mice by SMRT sequencing analysis showing efficiencies of segmental deletion (orange) 
and inversion (blue) outcomes. d, Stacked histogram for the percentages of indels recorded in full-length 
(3.6 kb), UMI-corrected SMRT reads after Hpd editing by AAV8 delivery of Dual-sgRNA:Designs 1 and 4 in 
C57BL/6 (left) and Fahneo/neo (right) mice. The plot indicates indels recorded only at gRNA-I (in red), indels 
only at gRNA-II (in dark green), and indels at both gRNA-I and gRNA-II (yellow) as measured by SMRT 
sequence analysis. e, mRNA levels from RNA-seq (transcripts per million) of Hpd wild-type mRNA in the 
livers of C57BL/6 mice (left) and Fahneo/neo mice (right). f, Volcano plots showing differentially expressed 
genes (red, FDR <= 5%) between dual-sgRNA:Design 1 and PBS treated Fahneo/neo mice (left) and Dual-
sgRNA:Design 4 and PBS-treated Fahneo/neo mice (right). g, RNA-seq normalized read coverage across 
Hpd exons shows a reduction of exon 4 expression in Dual-sgRNA:Design 1 and Design 4 treated 
Fahneo/neo mice and an increase in exon-exon junction reads skipping exons 3 and/or 4. h, Total HPD 
protein knockout as shown by anti-HPD Western blot using total protein collected from mouse liver 
homogenates. i, Representative images of immunostaining for HPD in liver tissues in Fahneo/neo mice 
injected with PBS (left) or Dual-sgRNA:Design 4 (right). Scale bar is 20 mm. Data are presented as mean 
values ± s.e.m. (n = 4 in C57BL/6 cohort; n = 1 in pre-NTBC Fahneo/neo cohort; n = 7 in post-NTBC Fahneo/neo 
cohort). 
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Fig. 3 | In vitro design and validation of all-in-one rAAV:HDR vectors. a, Schematic of four different 
vector designs of rAAV:HDR constructs containing an sgRNA expression cassette, Nme2Cas9, and a 
donor DNA (<500 bp) with and without flanking sgRNA target sites. b, Efficiencies of NHEJ and HDR 
events depicted as percentages of mCherry- and GFP-positive cells, respectively, obtained after 
transfection of AAV:Nme2Cas9:sgRNA and dsDNA GFP donor in trans), or of rAAV:HDR constructs in 
TLR-MCV1 HEK293T cells. Data are presented as mean values ± s.e.m. (n = 3 biological replicates). c, 
Schematic of modified rAAV packaging transfection system using anti-CRISPR protein plasmid to block 
self-targeting by Nme2Cas9 expression in packaging cells during production. 
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a 
Fig. 4 | rAAV:HDR vectors rescue liver disease phenotypes in a mouse model of HT-I. a, Schematic 
of rAAV:HDR:uncleaved and -cleaved vectors (left) and control non-cognate donor or spacer vectors (right) 
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to correct the Fah point mutation in FahPM/PM mice (top). b, In vivo experimental regimen to correct the Fah 
mutation by injection of AAV8 though the tail vein in adult FahPM/PM mice. c, Complete rescue of average 
body weight loss in FahPM/PM mice in treated cohorts injected with rAAV:HDR:uncleaved (red) and -cleaved 
(green), as compared to control cohorts injected with PBS (black), rAAV:FahDonor:ncSpacer (brown) or 
rAAV:ncDonor:FahSpacer (blue). Data shown represent the average body weight of each cohort. d, 
Stacked histograms showing the percentage distribution of NHEJ, HDR, and imprecise NHEJ:HDR mix at 
Fah in livers of mice 6 weeks after NTBC withdrawal, as measured by NGS sequencing of PCR amplicons 
from genomic DNA. e, Representative images of immunostaining for FAH in liver tissues of negative 
control and treated cohorts, as indicated below each panel. Scale bar, 100 mm. f, Levels of Fah mRNA 
from RNA-seq (transcripts per million) in the livers of FahPM/PM mice. g, Serum ALT activity in WT C57BL/6 
mice injected with PBS and rAAV:Nme2Cas9 vector targeting Rosa26 from a previous study, in 
comparison to untreated negative control and treated FahPM/PM mice. Statistical analysis used one-way 
ANOVA (p < 0.0001) with Dunnett's test. Data are presented as mean values ± s.e.m. **p = 0.0025, ****p < 
0.0001 vs. PBS-injected C57BL/6 group. h, Serum AST activity in WT C57BL/6 mice injected with PBS and 
rAAV:Nme2Cas9 vector targeting Rosa26 from a previous study, in comparison to untreated negative 
control and treated FahPM/PM mice. Statistical analysis used one-way ANOVA (p<0.0001) with Dunnett's 
test. Data are presented as mean values ± s.e.m. **p = 0.0011, ****p < 0.0001 vs PBS-injected C57BL/6 
group. Data are presented as mean values ± s.e.m. (n = 3 in PBS, rAAV:FahDonor:ncSpacer, 
rAAV:ncDonor:FahSpacer and pre-NTBC withdrawal AAV.HDR:cleaved and -uncleaved cohorts; n = 7 in 
post-NTBC withdrawal rAAV:HDR:cleaved and -uncleaved cohorts). 
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Fig. 5 | Reduced clinical disease manifestation in a mouse model of mucopolysaccharidosis type I 
treated with rAAV:HDR vectors. a, Schematic of rAAV:HDR:uncleaved, -cleaved, and control non-
cognate spacer vectors to correct the Idua point mutation in MPS-I IduaW392X mice. b, In vivo experimental  
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regimen to correct the Idua mutation by injection of rAAV9 though the facial vein in neonate MPS-I mice. c, 
IDUA specific activity in liver lysates of healthy mice compared to rAAV:IduaDonor:ncSpacer mice 
(negative control) and treated rAAV:HDR uncleaved/cleaved cohorts. The dashed lines indicate 0.2% 
(therapeutic threshold) and 3% of the IDUA activity detected in lysates from WT mice. d, Level of 
glycosaminoglycan (GAG) accumulation in the livers of the same mice shown in (c). e, Stacked histogram 
showing the percentage distribution of NHEJ, HDR and imprecise NHEJ:HDR mix at Idua in liver, brain, 
heart and muscle tissues, as measured by NGS sequencing of PCR amplicons from genomic DNA. f, qRT-
PCR data showing increase in Idua mRNA in the liver normalized to Gapdh mRNA. g, AAV copy numbers 
in MPS-I mouse liver tissues using the [sgRNA<>U6], [U6<>IduaDonor], [IduaDonor<>U1a] and 
[U1a<>Nme2Cas9] primer pairs. Data are presented as mean values ± s.e.m. (n= 4-5 biological replicates). 
p values are calculated using Student’s t-test (2-sided). 
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Supplementary Fig. 1 | sgRNA truncation and AAV:Nme2Cas9 vector minimization. a, Illustration of 
the 145-nt, full-length Nme.sgRNA, the truncated 121-nt Nme.sgRNA-121 and the further truncated 100-nt 
Nme.sgRNA-100. b, Comparison of editing efficiency with WT Nme.sgRNA, Nme.sgRNA-121 and 
Nme.sgRNA-100 by plasmid transfection at CYBB, LOC100505797 (in HEK293T) and Fah (in Neuro2a) 
genomic loci as estimated by TIDE analysis. c, Comparison of RNP editing efficiencies using full-length 
Nme.sgRNA and Nme.sgRNA-100, produced as T7 RNA polymerase transcripts (in vitro transcribed, IVT) 
with and without treatment with phosphatase (CIP), along with chemically synthesized, commercial 
Nme.sgRNA-100 guides. Nme2Cas9 RNPs targeting three genomic sites (TS6, TS16 and TS47) were 
electroporated into HEK293T and T lymphoblast MOLT-3 cells, and editing was assessed by TIDE analysis. 
d, Schematic of the ~4.7 kb (top) and the minimized ~4.4 kb (bottom) AAV vectors expressing Nme2Cas9 
and a 121nt sgRNA. ITR, inverted terminal repeats. Nme2Cas9 includes SV40 and nucleoplasmin NLSs on  
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the N and C termini, respectively. e, Comparison of editing efficiencies of the non-shortened 4.7 Kb and the 
shortened 4.4 Kb AAV:Nme2Cas9 constructs by plasmid transfection in TLR-Multi-Cas-Variant 1 (MCV1) 
lentivector-transduced HEK293T cells, as measured by flow cytometry. f, Comparison of editing efficiencies 
of the ~4.7 Kb and the shortened ~4.4 Kb AAV:Nme2Cas9 plasmids tested by transfection in Neuro2a cells 
(Pcsk9 and Fah) and HEK293T (VEGFA) and estimated by TIDE analysis. All data are presented as mean 
values ± s.e.m. (n = 3 biological replicates). 
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Supplementary Fig. 2 | In vivo editing 
using dual-sgRNA rAAV:Nme2Cas9 
vectors. a, Representative length 
distribution plots for mapped SMRT 
reads indicating the presence of 
segmental deletions in Neuro2a (N2A) 
cells after plasmid transfection, or in the 
livers of C57BL/6 and Fahneo/neo mice 
after AAV8 delivery. b, Anti-HPD 
immunostaining in liver tissues from 
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neo/neo mice injected with PBS or with AAV8:Nme2Cas9 Dual-sgRNA:Designs 1 and 4 vectors. c, rAAV 
fragment integration as detected by SMRT sequencing analysis. Data are presented as mean values ± 
s.e.m. (n = 4 in C57BL/6 cohort; n = 1 in pre-NTBC Fahneo/neo cohort; n = 7 in post-NTBC Fahneo/neo cohort). 
d, Proportions of exon-exon junction reads from RNA-seq data that support the inclusion of both exons 3 
and 4 (red), inclusion of only exon 3 (orange), and exclusion of both exons 3 and 4 (black) of Hpd in PBS-, 
Dual-sgRNA:Design 1-, and Dual-sgRNA:Design 4-treated Fahneo/neo mice. 
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Supplementary Fig. 3 | Improved molecular and pathological phenotypes of HT-I mice after 
treatment with rAAV:HDR vectors. a, Stacked histograms showing the percentages of NHEJ, HDR and 
imprecise NHEJ:HDR mix at the Fah editing site in livers of HT-I mice pre- and post-NTBC withdrawal, as 
measured by NGS sequencing of PCR amplicons. b, Agarose gel image showing the detection of RT-PCR 
products of Fah mRNA in liver lysate. The lower band (~300 bp) is from products with exon 8 skipped, while 
the ~400 bp band is from products that include exon 8. c, Representative H&E staining of liver from HT-I 
mice injected with PBS or negative control (rAAV:FahDonor:ncSpacer and rAAV:ncDonor:FahSpacer) 
vectors, or with rAAV:HDR:cleaved and -uncleaved vectors. Scale bars are 100 mm for the upper panels 
and 20 mm for the lower panels. d, Volcano plots showing significantly differentially-expressed genes (red, 
FDR <= 5%) between AAV:HDR:uncleaved and AAV:ncDonor:FahSpacer FahPM/PM mice (left) and 
AAV:HDR:cleaved and AAV:ncDonor:FahSpacer FahPM/PM mice (right). e, Volcano plot showing the paucity 
of significantly differentially expressed genes (red, FDR <= 5%) between AAV:HDR:uncleaved and 
AAV:HDR:cleaved FahPM/PM mice. Data are presented as mean values ± s.e.m. (n = 3 in PBS, 
rAAV:FahDonor:ncSpacer, rAAV:ncDonor:FahSpacer and pre-NTBC withdrawal AAV.HDR:cleaved and -
uncleaved cohorts; n = 7 in post-NTBC withdrawal rAAV:HDR:cleaved and -uncleaved cohorts). 
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Supplementary Fig. 4 | Anti-FAH immunostaining in liver tissues of all negative-control and treated 
cohorts. Vectors and drug regimens are indicated for each cohort. Scale bar, 100 mm. 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a







Supplementary Fig. 5 | Reduced rAAV copy number, Nme2Cas9 mRNA expression, and sgRNA 
expression in HT-I mice treated with rAAV:HDR:cleaved vectors. a, Schematic of qPCR assays to 
quantitate rAAV genome segment copy number in HT-I mouse liver samples. Primer pairs [U6<>FahDonor] 
and [FahDonor<>U1a] are indicated underneath. b, rAAV copy numbers in HT-I mouse liver tissues. rAAV 
copies are significantly reduced in rAAV:HDR:cleaved cohorts after NTBC withdrawal using the 
[U6<>FahDonor] primer pair (left); the lower values observed with the [FahDonor<>U1a] primer pair do not 
reach statistical significance. c, Steady-state mRNA levels from RNA-seq (polyA-enriched, transcripts per 
million) of Nme2Cas9 mRNA in the liver of FahPM/PM mice. d, qRT-PCR analyses with total RNA showing 
reduced Nme2Cas9 mRNA and sgRNA expression in the rAAV:HDR:cleaved cohort after NTBC 
withdrawal. e, Reduced fragment integration of rAAV vectors in the Fah locus in cohorts injected with the 
rAAV:HDR:cleaved vector, as detected by NGS analysis. Data are presented as mean values ± s.e.m. (n = 
3 in PBS, rAAV:FahDonor:ncSpacer, rAAV:ncDonor:FahSpacer and pre-NTBC withdrawal 
AAV:HDR:cleaved and -uncleaved cohorts; n = 7 in post-NTBC withdrawal rAAV:HDR:uncleaved and -
uncleaved cohorts). 
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Supplementary Fig. 6 | Reduced rAAV copy number, Nme2Cas9 mRNA expression, and sgRNA 
expression in MPS-I mice treated with rAAV:HDR:cleaved vectors. a, qRT-PCR data showing increase 
in Idua mRNA in the brain and muscle tissues as normalized to Gapdh mRNA. b, Schematic of qPCR 
assays to quantitate rAAV genome segment copy number in MPS-I mouse liver samples. Primer 
pairs  [sgRNA<>U6], [U6<>IduaDonor], [IduaDonor<>U1a] and [U1a<>Nme2Cas9] are indicated 
underneath. c,d Animals treated with rAAV:HDR:cleaved vectors exhibit reduced Nme2Cas9 mRNA (c) and 
sgRNA (d) expression levels as measured by qRT-PCR, though reductions do not reach statistical 
significance. e, Reduced fragment integration of rAAV vectors in the Idua locus in livers of cohorts injected 
with the rAAV:HDR:cleaved vector, as detected by NGS analysis. f, Humoral IgG1 immune response to 
Nme2Cas9 in vivo is significantly reduced in rAAV-treated, neonate-injected mice compared to adult-
injected cohorts. Data are presented as mean values ± s.e.m. (n = 3-5 biological replicates). 
b 
c d 
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Supplementary Note 
Nucleotide sequence of all plasmids 
pEJS1089 mini-AAV.sgRNA.Nme2Cas9 construct 
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pEJS1096: Dual-sgRNA.Design 1 construct 
Legend: ITR (first: U6 promoter GUIDE sequence sgRNA scaffold) (second: U6 promoter GUIDE sequence 
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pEJS1099: Dual-sgRNA.Design 4 construct 
Legend: ITR (first: sgRNA scaffold GUIDE sequence U6 promoter) U1a promoter NLS hNme2Cas9 NLS short-
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AAV:HDR:uncleaved-Design B Plasmid to correct eGfp in HEK293T TLR-Multi-Cas-Variant 1 (MCV1) 
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AAV:DR:cleaved-Design D Plasmid to correct eGfp in HEK293T TLR-Multi-Cas-Variant 1 (MCV1) 
Legend: ITR sgRNA scaffold eGFP GUIDE sequence U6 promoter eGFP Target_site-1 eGFP donor eGFP 
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Figure exemplifying the gating strategy of flow cytometry: 
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